2,3,6-trimethylimidazo[1,2-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2,3,6-trimethylimidazo[1,2-a]pyridine
• 化学式: C₁₀H₁₂N₂
• mdl: MFCD23714033
• 分子量: 160.219
• InChiKey: JZQGQWZPOCKOMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 、 2,3-丁二醇 在 tris(triphenylphosphine)ruthenium(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以49%的产率得到2,3,6-trimethylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  Ruthenium Complex-catalyzed Novel and Facile Synthesis of Imidazo[1,2-a]pyridines from 2-Aminopyridines andvicinal-Diols

  摘要：

  钌配合物催化下，2-氨基吡啶与邻二醇的N-杂环化反应为多种咪唑并[1,2-a]吡啶提供了新颖的合成方法。例如，在回流的二甘醇溶剂中，以催化量的RuCl2(PPh3)3为催化剂，2-氨基-4-甲基吡啶与1,2-环己二醇反应24小时，可得到产率为74%的2-甲基-6,7,8,9-四氢吡啶并[1,2-a]苯并咪唑。

  DOI：

  10.1246/cl.1993.1317

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DU TRANSPORT D'AMINES BIOGÈNES
  申请人：ANANTHAN SUBRAMANIAM

  公开号：WO2016090296A1

  公开（公告）日：2016-06-09

  The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及抑制生物胺转运体多巴胺转运体（DAT）、5-羟色胺转运体（SERT）和去甲肾上腺素转运体（NET）的某些融合双环杂环生物胺衍生物的化合物。本公开的化合物是多巴胺（DA）、5-羟色胺（5-HT）和去甲肾上腺素（NE）的重摄取的有效抑制剂，具有完全或部分最大效力。在抑制所有三种生物胺的重摄取中具有部分最大效力的化合物在此被称为部分三重摄取抑制剂（PTRIs）。本公开的化合物可用于治疗抑郁症、疼痛、物质滥用、物质滥用复发以及对可卡因、甲基苯丙胺、尼古丁和酒精等物质的成瘾。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意在限制本发明。
• Bicyclic aromatic substituted pyridone derivative
  申请人：Sakuraba Shunji

  公开号：US20090264426A1

  公开（公告）日：2009-10-22

  Disclosed is a compound represented by the formula (I): Wherein R 1 and R 2 independently represent a hydrogen atom, a lower alkyl group or the like; X 1 , X 2 and X 3 independently represent a methine group or a nitrogen atom; Y 1 and Y 3 independently represent a single bond, —O— or the like; Y 2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z 1 and Z 2 independently represent a single bond, a C 1-4 alkylene group or the like; Ar 1 represents an aromatic carbocyclic ring or the like; and Ar 2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

  本发明揭示了一种化合物，其化学式为（I）：其中R1和R2分别代表氢原子、低碳烷基或类似物；X1、X2和X3分别代表亚甲基基团或氮原子；Y1和Y3分别代表单键、—O—或类似物；Y2代表低碳烷基基团或类似物；W1至W4独立地代表单键、亚甲基基团或类似物；L代表单键、亚甲基基团或类似物；Z1和Z2独立地代表单键、C1-4烷基基团或类似物；Ar1代表芳香环烷基环或类似物；Ar2代表双环芳香环烷基环或类似物。该化合物可用作治疗中枢疾病、心血管疾病或代谢性疾病的药物。
• SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE
  申请人：Ando Makoto

  公开号：US20110071129A1

  公开（公告）日：2011-03-24

  [Problem] To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders. [Means for Resolution] Provided are compound of a formula (I): [wherein R 1 a and R 1 b each are a hydrogen atom, etc.; R 2 is a hydrogen atom, a C 1-6 alkyl, etc.; Ar 1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar 2 is a group to be formed by removing two hydrogen atoms from a 6-membered aromatic carbon ring, a 6-membered aromatic nitrogen-containing hetero ring, etc.; Ar 3 is a mono- or bi-cyclic aromatic carbon ring or aromatic hetero ring; m 1 , m 2 , m 3 and m 4 each are independently 0, 1, 2, 3 or 4, provided that the total of m 1 and m 2 is from 2 to 6, the total of m 3 and m 4 is from 2 to 6]. The compounds are useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders.

  [问题] 提供一种黑色素浓集激素受体拮抗剂，可用作中枢系统疾病、心血管疾病和代谢性疾病的药物。[解决方案] 提供了一种公式（I）的化合物：[其中R1a和R1b分别是氢原子等；R2是氢原子、C1-6烷基等；Ar1是6元芳香碳环基或6元芳香氮杂环基；Ar2是从6元芳香碳环、6元芳香氮杂环等中去除两个氢原子形成的基团；Ar3是单环或双环芳香碳环或芳香杂环；m1、m2、m3和m4各自独立地为0、1、2、3或4，前提是m1和m2的总和为2到6，m3和m4的总和为2到6]。这些化合物可用作中枢系统疾病、心血管疾病和代谢性疾病的药物。
• 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones
  申请人：Kesteleyn Rudolf Romanie Bart

  公开号：US20070265295A1

  公开（公告）日：2007-11-15

  1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones of formula (I): the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein n is 1, 2 or 3; R 1 is hydrogen, cyano, halo, substituted carbonyl, methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, Het 1 or Het 2 ; X is NR 2 , O, S, SO, SO 2 ; R 2 is hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, which are optionally substituted; R 2 is aryl substituted with —COOR 4 ; or R 2 is: —C p H 2p —CH(OR 14 )—C q H 2q —R 15 (b-3); —CH 2 —CH 2 —(O—CH 2 —CH 2 ) m —OR 14 (b-4); —CH 2 —CH 2 —(O—CH 2 —CH 2 ) m —NR 5a R 5b (b-5); -a 1 =a 2 -a 3 =a 4 - is —CH═CH—CH═CH—; —N═CH—CH═CH—; —CH═N—CH═CH—; —CH═CH—N═CH—; —CH═CH—CH═N—; wherein hydrogen atoms in (c-1)-(c-5) may be replaced by certain radicals; R 3 is a monocyclic or bicyclic aromatic heterocyclic ring system that can be substituted.

  公式（I）的1-杂环基-1,5-二氢-吡啶[3,2-b]吲哚-2-酮：其中n为1、2或3；R1为氢、氰基、卤素、取代的羰基、甲基亚胺基、N-羟基甲基亚胺基、单或双（C1-4烷基）甲基亚胺基、Het1或Het2；X为NR2、O、S、SO、SO2；R2为氢、C1-10烷基、C2-10烯基、C3-7环烷基，可选地取代；R2为芳基，取代为—COOR4；或R2为：—CpH2p—CH(OR14)—CqH2q—R15（b-3）；—CH2—CH2—（O—CH2—CH2）m—OR14（b-4）；—CH2—CH2—（O—CH2—CH2）m—NR5aR5b（b-5）；-a1=a2-a3=a4-为—CH═CH—CH═CH—；—N═CH—CH═CH—；—CH═N—CH═CH—；—CH═CH—N═CH—；—CH═CH—CH═N—；其中（c-1）-（c-5）中的氢原子可以被某些基团取代；R3为可取代的单环或双环芳香杂环环系。
• HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS
  申请人：ANANTHAN Subramaniam

  公开号：US20160159809A1

  公开（公告）日：2016-06-09

  The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及融合的双环杂环胺衍生物，其抑制生物胺转运体的胺重摄取功能，包括多巴胺转运体（DAT）、血清素转运体（SERT）和去甲肾上腺素转运体（NET）。本公开的化合物是多巴胺（DA）、血清素（5-羟色胺，5-HT）和去甲肾上腺素（NE）重摄取的有效抑制剂，具有完全或部分的最大功效。部分三重重摄取抑制剂（PTRIs）指部分最大功效抑制三种生物胺的重摄取的化合物。本公开的化合物可用于治疗抑郁症、疼痛和物质滥用以及物质滥用和对可卡因、甲基安非他明、尼古丁和酒精等物质成瘾的复发。该摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。